SARS CoV-2 ( COVID-19) Current Pharmacotherapy for Mother and Infant

被引：0
|
作者：
Thigpen, Jim [1 ]
机构：
[1] East Tennessee State Univ, Bill Gatton Coll Pharm, Johnson City, TN USA
来源：
NEONATAL NETWORK | 2021年 / 40卷 / 03期
关键词：
bamlanivimab; COVID-19; dexamethasone; hydroxychloroquine/chloroquine; ivermectin; lopinavir/ritonavir; remdesivir; SARS-Cov-2; vaccines; PREGNANCY OUTCOMES; WOMEN;
D O I：
10.1891/11-T-737
中图分类号：
R47 [护理学];
学科分类号：
1011 ;
摘要：
The novel coronavirus disease 2019 (COVID-19), appeared in the United States over 1 year ago. This virus has a wide range of presentations, from being asymptomatic to causing severe acute respiratory syndrome, which can lead to death. It has led to a worldwide effort to find effective treatments, from repurposed medications to new discoveries, as well as the push to develop effective vaccines. As the race to fight this pandemic unfolds, this column provides what is currently available to combat this virus, how it has been utilized in the pregnant population, and what data have been made available about how these treatments affect fetal development and the neonate.
引用
收藏
页码：175 / 182
页数：8
相关论文
共 50 条
  • [31] Candidate drugs against SARS-CoV-2 and COVID-19
    McKee, Dwight L.
    Sternberg, Ariane
    Stange, Ulrike
    Laufer, Stefan
    Naujokat, Cord
    PHARMACOLOGICAL RESEARCH, 2020, 157
  • [32] COVID-19 Pharmacotherapy in Pregnancy: A Literature Review of Current Therapeutic Choices
    Akinosoglou, Karolina
    Schinas, Georgios
    Rigopoulos, Emmanouil-Angelos
    Polyzou, Eleni
    Tzouvelekis, Argyrios
    Adonakis, George
    Gogos, Charalambos
    VIRUSES-BASEL, 2023, 15 (03):
  • [33] A guide to COVID-19 antiviral therapeutics: a summary and perspective of the antiviral weapons against SARS-CoV-2 infection
    Brady, Drugan K.
    Gurijala, Aashi R.
    Huang, Liyu
    Hussain, Ali A.
    Lingan, Audrey L.
    Pembridge, Olivia G.
    Ratangee, Brina A.
    Sealy, Tristan T.
    Vallone, Kyle T.
    Clements, Thomas P.
    FEBS JOURNAL, 2024, 291 (08) : 1632 - 1662
  • [34] Repurposing of antimycobacterium drugs for COVID-19 treatment by targeting SARS CoV-2 main protease: An in-silico perspective
    Chakraborty, Ayon
    Ghosh, Rajesh
    Mohapatra, Saswati Soumya
    Barik, Subhashree
    Biswas, Ashis
    Chowdhuri, Snehasis
    GENE, 2024, 922
  • [35] Editorial: Prophylactic efficacy and safety of COVID-19 vaccines in preventing disease caused by various SARS CoV-2 variants
    Mousa, Haidar Abdul-Lateef
    Ansari, Mairaj Ahmed
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2024, 14
  • [36] SARS-CoV-2 Vaccination in Patients with Cancer and COVID-19 in Mexico
    Barrientos-Flores, Corazon
    Vilar-Compte, Diana
    Martinez-Rivera, Nancy
    Villasenor-Echavarri, Rodrigo
    Martin-Onraet, Alexandra
    VACCINES, 2024, 12 (10)
  • [37] FrontierTherapeutics and Vaccine Strategies for SARS-CoV-2 (COVID-19): A Review
    Sheikhshahrokh, Amirhossein
    Ranjbar, Reza
    Saeidi, Elnaz
    Safarpoor Dehkordi, Farhad
    Heiat, Mohammad
    Ghasemi-Dehkordi, Payam
    Goodarzi, Hamed
    IRANIAN JOURNAL OF PUBLIC HEALTH, 2020, 49 : 18 - 29
  • [38] Editorial: SARS-CoV-2 Vaccine Responses and Breakthrough COVID-19
    Parums, Dinah, V
    MEDICAL SCIENCE MONITOR, 2021, 27
  • [39] SARS-CoV-2, COVID-19 and the eye: An update on published data
    Rousseau, A.
    Fenolland, J-R
    Labetoulle, M.
    JOURNAL FRANCAIS D OPHTALMOLOGIE, 2020, 43 (07): : 642 - 652
  • [40] Human coronaviruses: The emergence of SARS-CoV-2 and management of COVID-19
    Solomon, Magan
    Liang, Chen
    VIRUS RESEARCH, 2022, 319
12345